US Patent No: 5,117,830

Number of patents in Portfolio can not be more than 2000

Method of determining viability of tissue

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

A method and composition for determining the viability of tissue in a region of an organism having a vascular circulatory system that supplies blood to said region including the steps of dilating said vascular circulation system by introducing adenosine or an adenosine agonist into said vascular circulation system in order to increase the flow of blood into said region; introducing a blood flow marking medium into said region; alleviating the non-dilating effects of adenosine or said adenosine agonist by introducing an A.sub.1 adenosine receptor antagonist into said vascular circulatory system; and determining the amount of marking medium in said region. A composition is disclosed which includes the combination of adenosine or an adenosine agonist in combination with an A.sub.1 adenosine receptor which may be: ##STR1## wherein R.sub.1 is hydrogen or R.sub.2 ; R.sub.2 is selected from the group consisting of endo-2-norbornyl or cyclopentyl; R.sub.3 is selected from the group consisting of hydrogen, halogen, amine, carboxy, alkyl radicals having 1 to 10 carbon atoms, cycloalkyl radicals having from 3 to 8, preferably 5 to 6, ring carbon atoms, thio, sulfonate, sulfonamide, sulfon, sulfoxamide, phenyl, alkyl-substituted amine, and cycloalkyl substituted amine; R.sub.4 is selected from the group consisting of benzyl, phenyl, and alkyl groups comprising from 1 to 4 carbon atoms, wherein said alkyl group can be substituted with oxygen, for instance ethers and alcohols; and R.sub.5 is selected from the group consisting of hydrogen; hydroxy; sulfonate; halogen; alkoxy and cycloalkoxy groups comprising 1 to 6 carbon atoms.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ADERIS PHARMACEUTICALS, INC.RICHMOND, VA15

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Belardinelli, Luiz Palo Alto, CA 85 608
McAfee, Donald A Richmond, VA 7 106

Cited Art

Patent Info (Count) # Cites Year
 
ANGELLO, PAUL S., 1858 PALISADES TERRACE DRIVE, LAKE OSWEGO, OREGON 97034 (1)
4,824,660 Method of determining the viability of tissue in an organism 32 1985
 
DR. RENTSCHLER ARZNEIMITTEL GMBH & CO. (1)
4,855,300 Pharmaceutical composition for the treatment of circulatory disturbances 10 1987
 
MALLINCKRODT MEDICAL, INC. (1)
4,803,977 Method and apparatus for the diagnosis of respiratory diseases and allergies 15 1987
 
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (1)
4,788,500 Measurement of capillary flow using nuclear magnetic resonance 9 1987
 
UNIVERSITY OF VIRGINIA (1)
4,904,472 Use of adenosine antagonists in the treatment of bradyarrhythmias and mechanical dysfunction associated with cardiopulmonary resuscitation 43 1987

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
EURO-CELTIQUE S.A. (16)
5,939,422 Chemical compounds having PDE-IV inhibition activity 8 1996
5,864,037 Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity 19 1996
5,744,473 PDE IV inhibitors: "bis-compounds" 5 1996
5,889,014 Heterocyclic compounds for inhibiting phosphodiesterase IV 7 1996
5,922,751 Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same 8 1997
6,075,016 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity 3 1997
6,066,641 Aryl thioxanthines 4 1997
5,977,119 Trisubstituted thioxanthines 0 1997
6,025,361 Trisubstituted thioxanthines 4 1997
6,166,041 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma 26 1997
6,153,630 Phenylpyridyl compounds for inhibiting phosphodiesterase IV and methods of using same 6 1997
6,228,859 Purine derivatives having phosphodiesterase IV inhibition activity 7 1998
6,310,205 Hypoxathine compounds 4 1999
6,319,928 Purine derivatives having phosphodiesterase IV inhibition activity 7 1999
6,294,541 Purine derivatives having phosphodiesterase IV inhibition activity 5 1999
6,413,975 Purine derivatives having phosphodiesterase iv inhibition activity 4 2000
 
ADERIS PHARMACEUTICALS, INC. (3)
5,670,501 N-substituted 9-alkyladenines 2 1994
5,565,566 N.sup.6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists 4 1995
5,981,524 Substituted 9-alkyladenines 2 1997
 
GE HEALTHCARE AS (2)
6,375,931 Contrast agents 11 1999
6,811,766 Ultrasound imaging with contrast agent targeted to microvasculature and a vasodilator drug 2 2000
 
ACUSPHERE, INC. (1)
8,012,457 Ultrasound contrast agent dosage formulation 0 2005
 
COLORADO HEALTH CARE RESEARCH CORP. (1)
5,515,859 Myocardial infarction and ischemia detection method and apparatus 20 1993
 
CV THERAPEUTICS, INC. (1)
6,794,390 Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha 8 2001
 
DAINIPPON SUMITOMO PHARMA CO., LTD. (1)
6,028,076 Purine derivative 52 1998
 
EISAI R&D MANAGEMENT CO., LTD. (1)
6,841,549 Condensed imidazole compounds and a therapeutic agent for diabetes mellitus 14 2001
 
ENDACEA, INC. (1)
6,680,052 Methods of inhibiting tumor growth using adenosine receptor activated cells 1 1999
 
INSTITUTE OF EXPERIMENTAL BOTANY (1)
6,316,456 Purine derivatives having, in particular, antiproliferative properties, and their biological uses 15 1998
 
INSTITUTE OF EXPERIMENTAL BOTANY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (1)
8,163,762 Purine derivatives having, in particular, anti-proliferative properties, and their biological uses 0 2009
 
UCB PHARMA GMBH (1)
7,309,497 Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients 10 2001